Get the Stockscreener App
116.78
0.18%
0.21
After Hours:
116.78
Icon Plc stock is traded at $116.78, with a volume of 385.06K.
It is up +0.18% in the last 24 hours and up +1.17% over the past month.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
See More
Previous Close:
$116.57
Open:
$116.57
24h Volume:
385.06K
Relative Volume:
0.33
Market Cap:
$8.92B
Revenue:
$8.10B
Net Income/Loss:
$599.48M
P/E Ratio:
15.79
EPS:
7.3969
Net Cash Flow:
$971.25M
1W Performance:
+0.34%
1M Performance:
+1.17%
6M Performance:
-29.04%
1Y Performance:
-8.04%
1-Day Range:
$115.16
$119.55
1-Week Range:
$108.89
$120.00
52-Week Range:
$66.57
$211.00
Icon Plc Stock (ICLR) Company Profile
Compare ICLR vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
116.78 | 8.90B | 8.10B | 599.48M | 971.25M | 7.3969 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-23-26 | Upgrade | Jefferies | Hold → Buy |
| Feb-18-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-17-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Feb-12-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-12-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-08-26 | Downgrade | Truist | Buy → Hold |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Sep-09-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-03-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Aug-21-25 | Downgrade | Citigroup | Buy → Neutral |
| Jul-24-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
Hybrid Clinical Research Job at ICON | Life Science Graduates Must Apply! - BioTecNika
How Icon Plc (ICLR) Affects Rotational Strategy Timing - Stock Traders Daily
ICON earnings ahead: First results since accounting probe ends By Investing.com - Investing.com India
ICON earnings ahead: First results since accounting probe ends - Investing.com
Hybrid Clinical Research Associate Job at ICON plc | Apply Now - BioTecNika
ICON expands US early phase research capabilities with new clinic and outpatient centres - MSN
ICLR Stock Price, Quote & Chart | ICON PLC (NASDAQ:ICLR) - ChartMill
ICON plc stock (IE0005711209): clinical research specialist with fresh earnings in focus - AD HOC NEWS
ICON plc options imply 9.7% move in share price post-earnings - TipRanks
Templeton World Fund's Icon PLC(ICLR) Holding History - GuruFocus
ICON stock (IE0005711209): how the clinical research specialist is navigating post-pandemic demand - AD HOC NEWS
J.P. Morgan Maintains Icon PLC(ICLR.US) With Hold Rating, Cuts Target Price to $120 - Moomoo
ICLR SEC FilingsICON PLC 10-K, 10-Q, 8-K Forms - Stock Titan
Manhattan West Asset Management, LLC's Icon PLC(ICLR) Holding History - GuruFocus
Icon (ICLR) Receives Sector Perform Rating from RBC Capital - GuruFocus
Icon Set to Benefit From Rising Clinical Trial Activity, Strong Relationships With Large Pharma, RBC Says - Moomoo
Icon Is Maintained at Neutral by JP Morgan - Moomoo
Icon Price Target Announced at $123.00/Share by RBC Capital - Moomoo
RBC Capital resumes ICON stock coverage citing trial activity By Investing.com - Investing.com Australia
RBC Capital Initiates Icon PLC(ICLR.US) With Hold Rating, Announces Target Price $123 - Moomoo
ICON plc stock (IE0005711209): clinical research specialist after solid Q1 update - AD HOC NEWS
ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fra - GuruFocus
Harris Associates L.P. discloses 5.7% stake in ICON plc (ICLR) - Stock Titan
Orbis, Allan Gray file Schedule 13G/A for ICON PLC (ICLR) reporting 0 shares - Stock Titan
ICON PLC (NASDAQ: ICLR) director logs 5,005-option expiration extension - Stock Titan
ICON PLC (ICLR) director logs mixed transactions on 5,005 stock options - Stock Titan
ICON PLC (ICLR) director reshapes 3,255 stock options in Form 4 - Stock Titan
Wellington entities report 7.74% stake in Icon (ICLR) - Stock Titan
Icon Opens New Clinical Facilities in Move to Expand Early-Phase Capabilities - Moomoo
ICON plc stock (IE0005711209): Expands early-phase research with new Texas clinic - AD HOC NEWS
ICON opens new Texas clinical research unit - BioXconomy
ICON (ICLR) Expands Early Phase Capabilities with New Facilities - GuruFocus
A Look at Icon PLC (ICLR) After 3.7% Decline -- GF Value $241.78 vs Price $117.38 - GuruFocus
Icon announces new Clinical Research Unit in San Antonio, Texas - TipRanks
Icon Expands Early Phase Capabilities - Contract Pharma
ICON's New Texas Hub Aims to Reshape Early Phase Drug Trials - BriefGlance
Templeton Growth Fund, Inc.'s Icon PLC(ICLR) Holding History - GuruFocus
Does ICON (ICLR)ʼs 20‑F Delay Reshape the Narrative Around Its Strong Institutional Ownership Base? - Sahm
A Look at Icon PLC (ICLR) After 4.7% Decline -- GF Value $241.81 vs Price $118.96 - GuruFocus
Icon Plc $ICLR Shares Sold by Truist Financial Corp - MarketBeat
ICON earnings on deck: Can CRO move past accounting cloud? - Investing.com UK
Swedbank AB Has $7.05 Million Position in Icon Plc $ICLR - MarketBeat
ICON plc Delays Annual 20-F Amid Restatement - TipRanks
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):